VIDEO Update: Cyclacel Pharmaceuticals (NASDAQ: CYCC)
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop medicines, according to the company’s website (see here: www.cyclacel.com). SNNLive spoke with Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, Inc. at the BIO CEO & Investor Conference 2019.
The interview starts with a company overview provided by Mr. Rombotis and continues with an update since our last video interview (click here). Mr. Rombotis provides key information detailing pipeline clinical development and how their biotechnology is different when compared to their peers.
Our host then asks Spiro how their biopharmaceuticals are expected to be used: replace current standard of care or work with the current standard of care. Mr. Rombotis closes out the interview with his background and the company’s growth drivers for 2019.
For more information about Cyclacel Pharmaceuticals, please visit: www.cyclacel.com
The interview may contain forward-looking statements about Cyclacel Pharmaceuticals, Inc. See Cyclacel Pharmaceuticals, Inc.'s periodic filings with the Securities and Exchange Commission for more complete information.
Please read our full disclosure here.